Aprea Therapeutics (APRE), a clinical-stage biopharmaceutical company, on Wednesday provided an update on its intellectual property or IP portfolio, emphasizing its strong position in the DNA Damage Response or DDR cancer therapeutics field.
The company's ATR inhibitor program, which includes its lead candidate ATRN-119, is protected by four granted U.S. patents, one pending U.S. application, and numerous non-U.S. patents, extending exclusivity into 2044.
ATRN-119 is currently in clinical trials for advanced solid tumors. Additionally, Aprea's WEE1 kinase inhibitor program, led by APR-1051, is also supported by a strong patent estate, with exclusivity potentially lasting through 2043.
These strategic IP protections reinforce Aprea's goal to develop first-in-class and best-in-class oncology treatments with the potential to target cancers like ovarian, colorectal, prostate, and breast cancer.
The company is committed to securing global patent rights to advance its innovative cancer therapies while minimizing damage to healthy cells.
Currently, APRE is trading at $4.33 up by 8.91%
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.